DoW Breast Cancer, Clinical Research Extension Award

The FY26 Breast Cancer Research Program Clinical Research Extension Award, solicitation HT942526BCRPCREA2, is a grant opportunity issued by the Defense Health Agency Contracting Activity to support research that extends data collection, follow-up, and analysis of breast cancer clinical studies. The program aims to recover knowledge lost due to early trial termination, limited patient follow-up, or suboptimal data collection, including projects involving deeper molecular analysis of clinical samples. All applications must address at least one FY26 BCRP overarching challenge. The research team is required to include at least two breast cancer consumer advocates. Funding allows for a single Principal Investigator or a partnering arrangement between an Initiating PI and a Partnering PI. The application process is a two-step submission requiring a pre-application Letter of Intent by November 4, 2026, and a full application by November 18, 2026. Pre-applications are submitted via eBRAP, while full applications are submitted through eBRAP for intramural DOW organizations and Grants.gov for extramural organizations. Awards have a maximum period of performance of four years. Evaluation follows a two-tier system consisting of a peer review for technical merit and a programmatic review for relevance. Scored criteria include impact, research strategy and feasibility, partnership (for PPIO applications), and the research sharing plan. Applicants must be registered in SAM.gov with an active status and a Unique Entity Identifier.